glutathione 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1312 | 70-18-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hepatic function abnormal | 69.68 | 24.70 | 27 | 1247 | 34531 | 56256262 |
| Drug-induced liver injury | 36.27 | 24.70 | 17 | 1257 | 34445 | 56256348 |
| Eosinophilic pneumonia chronic | 30.33 | 24.70 | 5 | 1269 | 184 | 56290609 |
| Bowel movement irregularity | 27.00 | 24.70 | 8 | 1266 | 4515 | 56286278 |
| Defaecation urgency | 24.75 | 24.70 | 7 | 1267 | 3352 | 56287441 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hepatic function abnormal | 80.14 | 30.21 | 36 | 1127 | 41186 | 31654995 |
| Lymphocyte count decreased | 59.93 | 30.21 | 24 | 1139 | 20625 | 31675556 |
| Neutrophil count increased | 55.23 | 30.21 | 21 | 1142 | 15710 | 31680471 |
| Incision site pain | 50.33 | 30.21 | 12 | 1151 | 1822 | 31694359 |
| Platelet count decreased | 44.93 | 30.21 | 35 | 1128 | 110400 | 31585781 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hepatic function abnormal | 134.88 | 25.71 | 58 | 2228 | 67938 | 70858220 |
| Incision site pain | 72.44 | 25.71 | 17 | 2269 | 2744 | 70923414 |
| Neutrophil count increased | 63.53 | 25.71 | 26 | 2260 | 26769 | 70899389 |
| Lymphocyte count decreased | 60.40 | 25.71 | 29 | 2257 | 43510 | 70882648 |
| Platelet count decreased | 55.80 | 25.71 | 46 | 2240 | 178176 | 70747982 |
| Drug-induced liver injury | 53.44 | 25.71 | 29 | 2257 | 56084 | 70870074 |
| Alanine aminotransferase increased | 33.94 | 25.71 | 32 | 2254 | 147448 | 70778710 |
| Liver injury | 33.02 | 25.71 | 19 | 2267 | 41016 | 70885142 |
| White blood cell count increased | 30.57 | 25.71 | 22 | 2264 | 69551 | 70856607 |
| Red blood cells urine positive | 27.91 | 25.71 | 9 | 2277 | 4700 | 70921458 |
| Bone marrow failure | 27.44 | 25.71 | 18 | 2268 | 48992 | 70877166 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | V03AB32 | VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Antidotes |
| CHEBI has role | CHEBI:22586 | antioxidants |
| CHEBI has role | CHEBI:23357 | cofactor |
| CHEBI has role | CHEBI:75771 | Mus musculus metabolites |
| CHEBI has role | CHEBI:76971 | Escherichia coli metabolites |
| CHEBI has role | CHEBI:77746 | Homo sapiens metabolite |
| CHEBI has role | CHEBI:85046 | skin lightening agents |
| CHEBI has role | CHEBI:176497 | geroprotectors |
| CHEBI has role | CHEBI:75772 | S. cerevisiae metabolites |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 1.97 | acidic |
| pKa2 | 3.3 | acidic |
| pKa3 | 9.09 | acidic |
| pKa4 | 11.82 | acidic |
| pKa5 | 13.85 | acidic |
| pKa6 | 9.79 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Glutathione S-transferase kappa 1 | Enzyme | IC50 | 7.70 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4020562 | VUID |
| N0000148266 | NUI |
| D00014 | KEGG_DRUG |
| 4020562 | VANDF |
| C0017817 | UMLSCUI |
| CHEBI:16856 | CHEBI |
| 0P0 | PDB_CHEM_ID |
| CHEMBL1543 | ChEMBL_ID |
| DB00143 | DRUGBANK_ID |
| D005978 | MESH_DESCRIPTOR_UI |
| 124886 | PUBCHEM_CID |
| 6737 | IUPHAR_LIGAND_ID |
| GAN16C9B8O | UNII |
| 4890 | RXNORM |
| NOCODE | MMSL |
| 003447 | NDDF |
| 423272009 | SNOMEDCT_US |
| 55477000 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Bio-7 Serum | HUMAN OTC DRUG LABEL | 2 | 71583-1002 | LIQUID | 3 g | TOPICAL | unapproved drug other | 7 sections |
| Bio-7 | HUMAN OTC DRUG LABEL | 2 | 71583-1003 | CREAM | 3.26 g | TOPICAL | unapproved drug other | 7 sections |
| HARUTO HANGOVER DEFENCEPATCH | HUMAN OTC DRUG LABEL | 1 | 80094-0001 | PATCH | 1.42 mg | TOPICAL | unapproved drug other | 7 sections |
| Deyanling(Cranberry Flavored Collagen Peptide) | HUMAN OTC DRUG LABEL | 3 | 82570-004 | POWDER | 5 g | TOPICAL | unapproved drug other | 8 sections |